Naomi B. Haas, MD
Naomi B. Haas, MD
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
16 Penn Tower
3400 Spruce Street
Philadelphia, PA 19104
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-662-7402
Fax: 215-349-8550
Fax: 215-349-8550
Email:
naomi.haas@uphs.upenn.edu
naomi.haas@uphs.upenn.edu
Education:
B.S. (Integrated Life Sciences)
Kent State University, 1985.
M.D.
Northeastern Ohio Universities College of Medicine, 1985.
Permanent linkB.S. (Integrated Life Sciences)
Kent State University, 1985.
M.D.
Northeastern Ohio Universities College of Medicine, 1985.
Selected Publications
Haas Naomi B, Lin Xinyi, Manola Judith, Pins Michael, Liu Glenn, McDermott David, Nanus David, Heath Elisabeth, Wilding George, Dutcher Janice: A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Medical oncology (Northwood, London, England) 29(2): 761-7, Jun 2012.Swisher-McClure Samuel, Pollack Craig E, Christodouleas John P, Guzzo Thomas J, Haas Naomi B, Vapiwala Neha, Bekelman Justin E: Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. International journal of radiation oncology, biology, physics 83(1): 8-15, May 2012.
Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N. : Upfront Androgen Deprivation Therapy With Salvage Radiation May Improve Biochemical Outcomes in Prostate Cancer Patients With Post-Prostatectomy Rising PSA. Int J Radiat Oncol Biol Phys March 2012.
Jang Joanne W, Hwang Wei-Ting, Guzzo Thomas J, Wein Alan J, Haas Naomi B, Both Stefan, Vapiwala Neha: Upfront Androgen Deprivation Therapy With Salvage Radiation May Improve Biochemical Outcomes in Prostate Cancer Patients With Post-Prostatectomy Rising PSA. International journal of radiation oncology, biology, physics Mar 2012.
Haas N, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood CG, Matkins MB, Dutcher JJ, Dipaola RS : Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC) J Clin Oncol 30, 2012.
Beeram M, Patnaik A, Amaravadi RK, Haas NB, Papadopoulos KP, Tolcher AW, Smith LS, Harlacker K, Espino G, Drouin MA, Tawashi M, Wang J, Karam A, Hunt W, Maroun CA, Fournel M, Mehran M, Besterman JM, O'Dwyer PJ: MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel. J Clin Oncol 30, 2012 Notes: abstr e13604.
Smith M, Sweeney C, Rathkopf D, Scher H, Corn P, George D, Higano T, Yu E, Harzstarck A, Small E, Sartor O, Gordon M, Vogelzang N, Smith D, Hussain M, deBono J, Haas N, Scheffold C, Lee Y, Logothetis C.: Cabozantinib (Cabo) in Chemotherapy-pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): Results From a Phase 2 Non-Randomized Expansion Cohort (NRE). J Clin Oncol 30, 2012.
Yeboa Debra Nana, Guzzo Thomas, Mitra Nandita, Christodouleas John P, Haas Naomi B, Vapiwala Neha, Armstrong Katrina, Bekelman Justin E: Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. Urology 78(5): 1107-13, Nov 2011.
Smaldone Marc C, Fung Chunkit, Uzzo Robert G, Haas Naomi B: Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematology/oncology clinics of North America 25(4): 765-91, Aug 2011.
Slingluff Craig L, Petroni Gina R, Chianese-Bullock Kimberly A, Smolkin Mark E, Ross Merrick I, Haas Naomi B, von Mehren Margaret, Grosh William W: Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(21): 2924-32, Jul 2011.